AD/PD 2023 | Practical guidance for healthcare teams starting patients on LECIG
Dag Nyholm, MD, PhD, Uppsala University, Uppsala, Sweden, discusses the practical knowledge needed by healthcare teams with patients starting levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion. LECIG is a new treatment available to patients with Parkinson’s disease (PD) when oral PD therapy is no longer able to adequately control motor symptoms. Prof. Nyholm emphasizes that a sound knowledge of the tubing and pump apparatus is needed and after this point it is a relatively simple procedure. Previous knowledge of how to initiate levodopa-carbidopa intestinal gel (LCIG) or apomorphine infusion would give clinicians this understanding, as the devices are similar. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Prof. Nyholm has received grant support from EU Joint Programme – Neurodegenerative Disease Research (JPND), Swedish Brain Foundation, Swedish Parkinson’s Disease Foundation, Swedish Research Council, Vinnova (Sweden’s Innovation Agency); consultancy fees from Britannia, Medtronic, NeuroDerm, NordicInfu Care, Orion, Stada; lecture fees from AbbVie and Britannia; remuneration for participating in expert panels at the websites internetmedicin.se and netdoktor.se; and publishing royalties from Liber AB. He has participated as an investigator in clinical trials sponsored by Dizlin, GSK, Integrative Research Labs, Ipsen, Lobsor, Neurolixis, Sensidose, Solvay/Abbott/AbbVie.
